Short communication: the cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004

We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia. Using operational clinical and cost data, we calculated that the cost of treating leishmaniasis patients with standard pentavalent antimony was US$345 (95% CI 277–488) per patient treated and cured. The cost per DALY averted per patient cured with antimony was estimated to be approximately US$15 000 (95% CI 12 226–21 532).

• Autores: Vega, Juan Carlos; Sánchez Polania, Boris Fernando; Montero, Luz Mery; Rozo Montaña, Rafael Augusto; del Pilar Mahecha, Mercedes; Dueñes, Bladimir; Baron, Ángela Rocío; Reithinger, Richard
• Tipo de recurso: Article of journal
• Fecha de publicación: 2012
• Institución: Universidad El Bosque
• Repositorio: Repositorio U. El Bosque
• Idioma: eng
• OAI Identifier: oai:repositorio.unbosque.edu.co:20.500.12495/3801
• Acceso en línea: http://hdl.handle.net/20.500.12495/3801; https://doi.org/10.1111/j.1365-3156.2007.01962.x; https://repositorio.unbosque.edu.co
• Palabra clave: Cost-effectiveness analysis; Leishmaniasis; Prevention and control; Treatment
• Rights: openAccess
• License: Acceso abierto